Calcium Carbonate

Identification

Name
Calcium Carbonate
Accession Number
DB06724
Type
Small Molecule
Groups
Approved
Description

Calcium carbonate is an inorganic salt used as an antacid. It is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. Subsequent increases in pH may inhibit the action of pepsin. An increase in bicarbonate ions and prostaglandins may also confer cytoprotective effects. Calcium carbonate may also be used as a nutritional supplement or to treat hypocalcemia.

Structure
Thumb
Synonyms
  • CaCO3
  • Calcium carbonate
  • Calcium carbonate (1:1)
  • Calciumcarbonat
  • Carbonate de calcium
  • Carbonato de calcio
  • Carbonic acid calcium salt (1:1)
  • Chalk
  • E 170
  • Kalziumkarbonat
  • Kohlensaurer kalk
  • Precipitated calcium carbonate
External IDs
CI 77220 / E-170(I) / INS NO.170(I) / INS-170(I) / NDI 443
Product Images
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
7 Select AntacidTablet, chewable750 mg/1Oral7 Eleven2014-09-11Not applicableUs
Alka SeltzerTablet, chewable750 mg/1OralBest Co2013-02-08Not applicableUs
Alka-Seltzer Extra Strength Heartburn ReliefChewsTablet, chewable750 mg/1OralBayer Health Care Llc.2016-09-15Not applicableUs
Alka-Seltzer Fruit ChewsTablet, chewable750 mg/1OralBayer Health Care Llc, Consumer Care2013-03-15Not applicableUs
Alka-Seltzer Heartburn ReliefChewsTablet, chewable750 mg/1OralBayer2014-03-15Not applicableUs
Alka-Seltzer Heartburn ReliefChews Cool MintTablet, chewable750 mg/1OralBayer Health Care Llc.2014-03-152017-05-31Us
Alka-Seltzer Heartburn ReliefChews StrawberryTablet, chewable750 mg/1OralBayer Health Care Llc.2014-03-152017-08-31Us
Alka-Seltzer Heartburn ReliefChews Strawberry and OrangeTablet, chewable750 mg/1OralBayer2014-03-15Not applicableUs
Alkums antacidTablet, chewable500 mg/1OralGuardian Drug Company2012-02-01Not applicableUs
AntacidTablet, chewable750 mg/1OralWalgreen2016-03-24Not applicableUs
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apatite ProfessionalPaste36.4 g/130gDentalSungwon Pharmaceutical Co., Ltd.2013-03-14Not applicableUs
Insan Bamboosalt toothpastePaste, dentifrice31.25 g/100gDentalInsan Bamboo Salt Inc2011-02-13Not applicableUs
Obeo The Mee Dental CarePaste51 g/150gDentalC Pbio Co., Ltd2016-12-282017-05-18Us
SolmeetPaste, dentifrice15.85 g/100gDentalSolm Co., Ltd.2016-05-12Not applicableUs
TumsTablet500 mg/1OralCardinal Health2011-06-15Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Acid Controller CompleteCalcium Carbonate (800 mg/1) + Famotidine (10 mg/1) + Magnesium Hydroxide (165 mg/1)Tablet, chewableOralShopko Stores Operating2013-06-05Not applicableUs
Acid Controller CompleteCalcium Carbonate (800 mg/1) + Famotidine (10 mg/1) + Magnesium Hydroxide (165 mg/1)Tablet, chewableOralSafeway2008-08-06Not applicableUs
Acid Controller CompleteCalcium Carbonate (800 mg/1) + Famotidine (10 mg/1) + Magnesium Hydroxide (165 mg/1)Tablet, chewableOralShopko Stores Operating2013-06-05Not applicableUs
Acid Controller Complete dual actionCalcium Carbonate (800 mg/1) + Famotidine (10 mg/1) + Magnesium Hydroxide (165 mg/1)Tablet, chewableOralWalgreen2008-07-30Not applicableUs
Acid Controller Complete dual actionCalcium Carbonate (800 mg/1) + Famotidine (10 mg/1) + Magnesium Hydroxide (165 mg/1)Tablet, chewableOralWalgreen2008-07-30Not applicableUs
Acid Reducer CompleteCalcium Carbonate (800 mg/1) + Famotidine (10 mg/1) + Magnesium Hydroxide (165 mg/1)Tablet, chewableOralShopko Stores Operating2016-01-06Not applicableUs
Acid Reducer CompleteCalcium Carbonate (800 mg/1) + Famotidine (10 mg/1) + Magnesium Hydroxide (165 mg/1)Tablet, chewableOralShopko Stores Operating2016-01-12Not applicableUs
Acid Reducer CompleteCalcium Carbonate (800 mg/1) + Famotidine (10 mg/1) + Magnesium Hydroxide (165 mg/1)Tablet, chewableOralWalgreen2016-01-29Not applicableUs
Acid Reducer CompleteCalcium Carbonate (800 mg/1) + Famotidine (10 mg/1) + Magnesium Hydroxide (165 mg/1)Tablet, chewableOralRite Aid2009-05-15Not applicableUs
Acid Reducer CompleteCalcium Carbonate (800 mg/1) + Famotidine (10 mg/1) + Magnesium Hydroxide (165 mg/1)Tablet, chewableOralWalgreen2016-01-29Not applicableUs
Categories
UNII
H0G9379FGK
CAS number
471-34-1
Weight
Average: 100.087
Monoisotopic: 99.947335021
Chemical Formula
CCaO3
InChI Key
VTYYLEPIZMXCLO-UHFFFAOYSA-L
InChI
InChI=1S/CH2O3.Ca/c2-1(3)4;/h(H2,2,3,4);/q;+2/p-2
IUPAC Name
calcium carbonate
SMILES
[Ca++].[O-]C([O-])=O

Pharmacology

Indication

For relief of heartburn and acid indigestion. May also be used as a nutritional supplement or to treat hypocalcemia.

Structured Indications
Pharmacodynamics

Gastric-peptic disease occurs as a result of an imbalance between protective factors, such as mucus, bicarbonate, and prostaglandin secretion, and aggressive factors, such as hydrochloric acid, pepsin, and Helicobacter pylori (H. pylori). Antacids work by restoring acid-base balance, attenuating the pepsin activity and increasing bicarbonate and prostaglandin secretion. The acid-neutralizing capacity of calcium carbonate is 58 mEq/15 ml. When used as a nutritional supplement, calcium carbonate acts by directly increasing calcium stores within the body.

Mechanism of action

Calcium carbonate is a basic inorganic salt that acts by neutralizing hydrochloric acid in gastric secretions. It also inhibits the action of pepsin by increasing the pH and via adsorption. Cytoprotective effects may occur through increases in bicarbonate ion (HCO3-) and prostaglandins. Neutralization of hydrochloric acid results in the formation of calcium chloride, carbon dioxide and water. Approximately 90% of calcium chloride is converted to insoluble calcium salts (e.g. calcium carbonate and calcium phosphate).

Absorption

Maximal absorption occurs at doses of 500 mg or less taken with food. Oral bioavailability depends on intestinal pH, the presence of food and dosage.

Volume of distribution

Calcium is rapidly distributed taken up by skeletal tissues following absorption and distribution into extracellular fluids. Bone contains 99% of the body's calcium and the remaining 1% is approximately equally distributed between intracellular and extracellular fluids.

Protein binding

Calcium acts as a co-factor to numerous enzymes.

Metabolism

None.

Route of elimination

Excreted mainly in the feces. The majority of renally filtered calcium is reabsorbed in the ascending limb of the loop of Henle and the proximal and distal convoluted tubules. Also secreted by sweat glands.

Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe bioavailability of 16-Bromoepiandrosterone can be decreased when combined with Calcium Carbonate.Investigational
19-norandrostenedioneThe bioavailability of 19-norandrostenedione can be decreased when combined with Calcium Carbonate.Experimental, Illicit
2,5-Dimethoxy-4-ethylamphetamineCalcium Carbonate may decrease the excretion rate of 2,5-Dimethoxy-4-ethylamphetamine which could result in a higher serum level.Experimental, Illicit
3,4-MethylenedioxyamphetamineCalcium Carbonate may decrease the excretion rate of 3,4-Methylenedioxyamphetamine which could result in a higher serum level.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineCalcium Carbonate may decrease the excretion rate of 4-Bromo-2,5-dimethoxyamphetamine which could result in a higher serum level.Experimental, Illicit
5-androstenedioneThe bioavailability of 5-androstenedione can be decreased when combined with Calcium Carbonate.Experimental, Illicit
AcepromazineCalcium Carbonate can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
AceprometazineCalcium Carbonate can cause a decrease in the absorption of Aceprometazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AcetyldigitoxinCalcium Carbonate may increase the arrhythmogenic activities of Acetyldigitoxin.Approved
AcetyldigoxinCalcium Carbonate may increase the arrhythmogenic activities of Acetyldigoxin.Experimental
AlclometasoneThe bioavailability of Alclometasone can be decreased when combined with Calcium Carbonate.Approved
AldosteroneThe bioavailability of Aldosterone can be decreased when combined with Calcium Carbonate.Experimental
Alendronic acidThe serum concentration of Alendronic acid can be decreased when it is combined with Calcium Carbonate.Approved
AlimemazineCalcium Carbonate can cause a decrease in the absorption of Alimemazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
AllopurinolCalcium Carbonate can cause a decrease in the absorption of Allopurinol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AmcinonideThe bioavailability of Amcinonide can be decreased when combined with Calcium Carbonate.Approved
AmlodipineThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Calcium Carbonate.Approved
AmphetamineCalcium Carbonate may decrease the excretion rate of Amphetamine which could result in a higher serum level.Approved, Illicit
AmrinoneThe therapeutic efficacy of Amrinone can be decreased when used in combination with Calcium Carbonate.Approved
AndrostenedioneThe bioavailability of Androstenedione can be decreased when combined with Calcium Carbonate.Experimental, Illicit
AnecortaveThe bioavailability of Anecortave can be decreased when combined with Calcium Carbonate.Investigational
anecortave acetateThe bioavailability of anecortave acetate can be decreased when combined with Calcium Carbonate.Investigational
AtamestaneThe bioavailability of Atamestane can be decreased when combined with Calcium Carbonate.Investigational
AtazanavirCalcium Carbonate can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
AtorvastatinThe serum concentration of Atorvastatin can be decreased when it is combined with Calcium Carbonate.Approved
AzelnidipineThe therapeutic efficacy of Azelnidipine can be decreased when used in combination with Calcium Carbonate.Approved
AzimilideThe therapeutic efficacy of Azimilide can be decreased when used in combination with Calcium Carbonate.Investigational
BarnidipineThe therapeutic efficacy of Barnidipine can be decreased when used in combination with Calcium Carbonate.Approved
Beclomethasone dipropionateThe bioavailability of Beclomethasone dipropionate can be decreased when combined with Calcium Carbonate.Approved, Investigational
BencyclaneThe therapeutic efficacy of Bencyclane can be decreased when used in combination with Calcium Carbonate.Experimental
BendroflumethiazideBendroflumethiazide may decrease the excretion rate of Calcium Carbonate which could result in a higher serum level.Approved
BenidipineThe therapeutic efficacy of Benidipine can be decreased when used in combination with Calcium Carbonate.Approved
BenzphetamineCalcium Carbonate may decrease the excretion rate of Benzphetamine which could result in a higher serum level.Approved, Illicit
BepridilThe therapeutic efficacy of Bepridil can be decreased when used in combination with Calcium Carbonate.Approved, Withdrawn
BetamethasoneThe bioavailability of Betamethasone can be decreased when combined with Calcium Carbonate.Approved, Vet Approved
BisacodylThe therapeutic efficacy of Bisacodyl can be decreased when used in combination with Calcium Carbonate.Approved
Bismuth SubcitrateThe therapeutic efficacy of Bismuth Subcitrate can be decreased when used in combination with Calcium Carbonate.Approved
BL-1020Calcium Carbonate can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Calcium Carbonate.Approved
BudesonideThe bioavailability of Budesonide can be decreased when combined with Calcium Carbonate.Approved
CalcidiolThe risk or severity of adverse effects can be increased when Calcium Carbonate is combined with Calcidiol.Approved, Nutraceutical
CalcipotriolThe risk or severity of adverse effects can be increased when Calcium Carbonate is combined with Calcipotriol.Approved
Calcium AcetateThe risk or severity of adverse effects can be increased when Calcium Carbonate is combined with Calcium Acetate.Approved
CaptoprilThe serum concentration of Captopril can be decreased when it is combined with Calcium Carbonate.Approved
CarboxyamidotriazoleThe therapeutic efficacy of Carboxyamidotriazole can be decreased when used in combination with Calcium Carbonate.Investigational
CaroverineThe therapeutic efficacy of Caroverine can be decreased when used in combination with Calcium Carbonate.Experimental
CefditorenThe serum concentration of Cefditoren can be decreased when it is combined with Calcium Carbonate.Approved
CefpodoximeThe serum concentration of Cefpodoxime can be decreased when it is combined with Calcium Carbonate.Approved, Vet Approved
CeftriaxoneThe risk or severity of adverse effects can be increased when Calcium Carbonate is combined with Ceftriaxone.Approved
CefuroximeThe serum concentration of Cefuroxime can be decreased when it is combined with Calcium Carbonate.Approved
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Calcium Carbonate.Withdrawn
ChloroquineThe serum concentration of Chloroquine can be decreased when it is combined with Calcium Carbonate.Approved, Vet Approved
ChlorothiazideChlorothiazide may decrease the excretion rate of Calcium Carbonate which could result in a higher serum level.Approved, Vet Approved
ChlorphentermineCalcium Carbonate may decrease the excretion rate of Chlorphentermine which could result in a higher serum level.Illicit, Withdrawn
ChlorproethazineCalcium Carbonate can cause a decrease in the absorption of Chlorproethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
ChlorpromazineCalcium Carbonate can cause a decrease in the absorption of Chlorpromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
ChlortetracyclineCalcium Carbonate can cause a decrease in the absorption of Chlortetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
ChlorthalidoneChlorthalidone may decrease the excretion rate of Calcium Carbonate which could result in a higher serum level.Approved
CiclesonideThe bioavailability of Ciclesonide can be decreased when combined with Calcium Carbonate.Approved, Investigational
CilnidipineThe therapeutic efficacy of Cilnidipine can be decreased when used in combination with Calcium Carbonate.Approved
CinnarizineThe therapeutic efficacy of Cinnarizine can be decreased when used in combination with Calcium Carbonate.Approved
CinoxacinCalcium Carbonate can cause a decrease in the absorption of Cinoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
ClevidipineThe therapeutic efficacy of Clevidipine can be decreased when used in combination with Calcium Carbonate.Approved
ClobetasolThe bioavailability of Clobetasol can be decreased when combined with Calcium Carbonate.Investigational
Clobetasol propionateThe bioavailability of Clobetasol propionate can be decreased when combined with Calcium Carbonate.Approved
ClobetasoneThe bioavailability of Clobetasone can be decreased when combined with Calcium Carbonate.Approved
ClocortoloneThe bioavailability of Clocortolone can be decreased when combined with Calcium Carbonate.Approved
Clodronic AcidThe serum concentration of Clodronic Acid can be decreased when it is combined with Calcium Carbonate.Approved, Investigational, Vet Approved
Cortexolone 17α-propionateThe bioavailability of Cortexolone 17α-propionate can be decreased when combined with Calcium Carbonate.Investigational
CorticosteroneThe bioavailability of Corticosterone can be decreased when combined with Calcium Carbonate.Experimental
Cortisone acetateThe bioavailability of Cortisone acetate can be decreased when combined with Calcium Carbonate.Approved
CyclopenthiazideCyclopenthiazide may decrease the excretion rate of Calcium Carbonate which could result in a higher serum level.Experimental
CymarinCalcium Carbonate may increase the arrhythmogenic activities of Cymarin.Experimental
CysteamineThe therapeutic efficacy of Cysteamine can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Calcium Carbonate.Approved
DabrafenibThe serum concentration of Dabrafenib can be decreased when it is combined with Calcium Carbonate.Approved
DarodipineThe therapeutic efficacy of Darodipine can be decreased when used in combination with Calcium Carbonate.Experimental
DasatinibCalcium Carbonate can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
DeferiproneThe serum concentration of Deferiprone can be decreased when it is combined with Calcium Carbonate.Approved
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Calcium Carbonate.Approved
DemeclocyclineCalcium Carbonate can cause a decrease in the absorption of Demeclocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DeslanosideCalcium Carbonate may increase the arrhythmogenic activities of Deslanoside.Approved
DesoximetasoneThe bioavailability of Desoximetasone can be decreased when combined with Calcium Carbonate.Approved
Desoxycorticosterone acetateThe bioavailability of Desoxycorticosterone acetate can be decreased when combined with Calcium Carbonate.Approved
Desoxycorticosterone PivalateThe bioavailability of Desoxycorticosterone Pivalate can be decreased when combined with Calcium Carbonate.Experimental, Vet Approved
DexamethasoneThe bioavailability of Dexamethasone can be decreased when combined with Calcium Carbonate.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe bioavailability of Dexamethasone isonicotinate can be decreased when combined with Calcium Carbonate.Vet Approved
DexmethylphenidateCalcium Carbonate can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved
DextroamphetamineCalcium Carbonate may decrease the excretion rate of Dextroamphetamine which could result in a higher serum level.Approved, Illicit
DiethylpropionCalcium Carbonate may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Approved, Illicit
DiflorasoneThe bioavailability of Diflorasone can be decreased when combined with Calcium Carbonate.Approved
DifluocortoloneThe bioavailability of Difluocortolone can be decreased when combined with Calcium Carbonate.Approved
DifluprednateThe bioavailability of Difluprednate can be decreased when combined with Calcium Carbonate.Approved
DigitoxinCalcium Carbonate may increase the arrhythmogenic activities of Digitoxin.Approved
DigoxinCalcium Carbonate may increase the arrhythmogenic activities of Digoxin.Approved
DihydrotachysterolThe risk or severity of adverse effects can be increased when Calcium Carbonate is combined with Dihydrotachysterol.Approved
DiltiazemThe therapeutic efficacy of Diltiazem can be decreased when used in combination with Calcium Carbonate.Approved
Dipotassium phosphateCalcium Carbonate can cause a decrease in the absorption of Dipotassium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DobutamineThe therapeutic efficacy of Dobutamine can be decreased when used in combination with Calcium Carbonate.Approved
DolutegravirThe serum concentration of Dolutegravir can be decreased when it is combined with Calcium Carbonate.Approved
DotarizineThe therapeutic efficacy of Dotarizine can be decreased when used in combination with Calcium Carbonate.Investigational
DoxercalciferolThe risk or severity of adverse effects can be increased when Calcium Carbonate is combined with Doxercalciferol.Approved
DoxycyclineCalcium Carbonate can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
EfonidipineThe therapeutic efficacy of Efonidipine can be decreased when used in combination with Calcium Carbonate.Approved
EltrombopagThe serum concentration of Eltrombopag can be decreased when it is combined with Calcium Carbonate.Approved
ElvitegravirThe serum concentration of Elvitegravir can be decreased when it is combined with Calcium Carbonate.Approved
EnoxacinCalcium Carbonate can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
EperisoneThe therapeutic efficacy of Eperisone can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
EquileninThe bioavailability of Equilenin can be decreased when combined with Calcium Carbonate.Experimental
EquilinThe bioavailability of Equilin can be decreased when combined with Calcium Carbonate.Approved
ErgocalciferolThe risk or severity of adverse effects can be increased when Calcium Carbonate is combined with Ergocalciferol.Approved, Nutraceutical
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Calcium Carbonate.Approved, Investigational
EstramustineCalcium Carbonate can cause a decrease in the absorption of Estramustine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
EstroneThe bioavailability of Estrone can be decreased when combined with Calcium Carbonate.Approved
Estrone sulfateThe bioavailability of Estrone sulfate can be decreased when combined with Calcium Carbonate.Approved
Etidronic acidThe serum concentration of Etidronic acid can be decreased when it is combined with Calcium Carbonate.Approved
FelodipineThe therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
FendilineThe therapeutic efficacy of Fendiline can be decreased when used in combination with Calcium Carbonate.Withdrawn
Ferric CarboxymaltoseCalcium Carbonate can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric CitrateCalcium Carbonate can cause a decrease in the absorption of Ferric Citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric pyrophosphateCalcium Carbonate can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FexofenadineThe serum concentration of Fexofenadine can be decreased when it is combined with Calcium Carbonate.Approved
FleroxacinCalcium Carbonate can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
fluasteroneThe bioavailability of fluasterone can be decreased when combined with Calcium Carbonate.Investigational
FludrocortisoneThe bioavailability of Fludrocortisone can be decreased when combined with Calcium Carbonate.Approved
FlumequineCalcium Carbonate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
FlumethasoneThe bioavailability of Flumethasone can be decreased when combined with Calcium Carbonate.Approved, Vet Approved
FlunarizineThe therapeutic efficacy of Flunarizine can be decreased when used in combination with Calcium Carbonate.Approved
Fluocinolone AcetonideThe bioavailability of Fluocinolone Acetonide can be decreased when combined with Calcium Carbonate.Approved, Investigational, Vet Approved
FluocinonideThe bioavailability of Fluocinonide can be decreased when combined with Calcium Carbonate.Approved, Investigational
FluocortoloneThe bioavailability of Fluocortolone can be decreased when combined with Calcium Carbonate.Approved, Withdrawn
FluorometholoneThe bioavailability of Fluorometholone can be decreased when combined with Calcium Carbonate.Approved
FluphenazineCalcium Carbonate can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FluprednideneThe bioavailability of Fluprednidene can be decreased when combined with Calcium Carbonate.Approved, Withdrawn
FluprednisoloneThe bioavailability of Fluprednisolone can be decreased when combined with Calcium Carbonate.Approved
FlurandrenolideThe bioavailability of Flurandrenolide can be decreased when combined with Calcium Carbonate.Approved
FluvastatinThe serum concentration of Fluvastatin can be decreased when it is combined with Calcium Carbonate.Approved
FormestaneThe bioavailability of Formestane can be decreased when combined with Calcium Carbonate.Approved, Investigational, Withdrawn
FosinoprilThe serum concentration of Fosinopril can be decreased when it is combined with Calcium Carbonate.Approved
GabapentinThe serum concentration of Gabapentin can be decreased when it is combined with Calcium Carbonate.Approved, Investigational
GallopamilThe therapeutic efficacy of Gallopamil can be decreased when used in combination with Calcium Carbonate.Investigational
GarenoxacinCalcium Carbonate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
GatifloxacinCalcium Carbonate can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Calcium Carbonate.Approved, Investigational
GemifloxacinCalcium Carbonate can cause a decrease in the absorption of Gemifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
GepefrineCalcium Carbonate may decrease the excretion rate of Gepefrine which could result in a higher serum level.Experimental
GitoformateCalcium Carbonate may increase the arrhythmogenic activities of Gitoformate.Experimental
GrepafloxacinCalcium Carbonate can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
HE3286The bioavailability of HE3286 can be decreased when combined with Calcium Carbonate.Investigational
HydrochlorothiazideHydrochlorothiazide may decrease the excretion rate of Calcium Carbonate which could result in a higher serum level.Approved, Vet Approved
HydrocortisoneThe bioavailability of Hydrocortisone can be decreased when combined with Calcium Carbonate.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may decrease the excretion rate of Calcium Carbonate which could result in a higher serum level.Approved
HydroxyamphetamineCalcium Carbonate may decrease the excretion rate of Hydroxyamphetamine which could result in a higher serum level.Approved
HyoscyamineThe serum concentration of Hyoscyamine can be decreased when it is combined with Calcium Carbonate.Approved
IbandronateThe serum concentration of Ibandronate can be decreased when it is combined with Calcium Carbonate.Approved, Investigational
IndapamideIndapamide may decrease the excretion rate of Calcium Carbonate which could result in a higher serum level.Approved
Iofetamine I-123Calcium Carbonate may decrease the excretion rate of Iofetamine I-123 which could result in a higher serum level.Approved
IronCalcium Carbonate can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Iron DextranCalcium Carbonate can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Iron saccharateCalcium Carbonate can cause a decrease in the absorption of Iron saccharate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
IsoniazidCalcium Carbonate can cause a decrease in the absorption of Isoniazid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
IsradipineThe therapeutic efficacy of Isradipine can be decreased when used in combination with Calcium Carbonate.Approved
IstaroximeThe bioavailability of Istaroxime can be decreased when combined with Calcium Carbonate.Investigational
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Calcium Carbonate.Approved, Investigational
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Calcium Carbonate.Approved, Investigational
LacidipineThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Calcium Carbonate.Approved
LamotrigineThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
Lanatoside CCalcium Carbonate may increase the arrhythmogenic activities of Lanatoside C.Experimental
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Calcium Carbonate.Approved
LercanidipineThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
LevofloxacinCalcium Carbonate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
LevothyroxineThe therapeutic efficacy of Levothyroxine can be decreased when used in combination with Calcium Carbonate.Approved
LidoflazineThe therapeutic efficacy of Lidoflazine can be decreased when used in combination with Calcium Carbonate.Experimental
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Calcium Carbonate.Approved, Vet Approved
LiotrixThe therapeutic efficacy of Liotrix can be decreased when used in combination with Calcium Carbonate.Approved
Lipoic AcidCalcium Carbonate can cause a decrease in the absorption of Lipoic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Nutraceutical
LisdexamfetamineCalcium Carbonate may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level.Approved, Investigational
LovastatinThe serum concentration of Lovastatin can be decreased when it is combined with Calcium Carbonate.Approved, Investigational
Magnesium SulfateThe therapeutic efficacy of Magnesium Sulfate can be decreased when used in combination with Calcium Carbonate.Approved, Vet Approved
ManidipineThe therapeutic efficacy of Manidipine can be decreased when used in combination with Calcium Carbonate.Approved
ME-609The bioavailability of ME-609 can be decreased when combined with Calcium Carbonate.Investigational
MecamylamineThe serum concentration of Mecamylamine can be increased when it is combined with Calcium Carbonate.Approved
MedrysoneThe bioavailability of Medrysone can be decreased when combined with Calcium Carbonate.Approved
MelengestrolThe bioavailability of Melengestrol can be decreased when combined with Calcium Carbonate.Vet Approved
MemantineThe serum concentration of Memantine can be increased when it is combined with Calcium Carbonate.Approved, Investigational
MephedroneCalcium Carbonate may decrease the excretion rate of Mephedrone which could result in a higher serum level.Investigational
MephentermineCalcium Carbonate may decrease the excretion rate of Mephentermine which could result in a higher serum level.Approved
MesalazineThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Calcium Carbonate.Approved
MesoridazineCalcium Carbonate can cause a decrease in the absorption of Mesoridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MethamphetamineCalcium Carbonate may decrease the excretion rate of Methamphetamine which could result in a higher serum level.Approved, Illicit
MethenamineThe therapeutic efficacy of Methenamine can be decreased when used in combination with Calcium Carbonate.Approved, Vet Approved
MethotrimeprazineCalcium Carbonate can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MethoxyphenamineCalcium Carbonate may decrease the excretion rate of Methoxyphenamine which could result in a higher serum level.Experimental
MethyclothiazideMethyclothiazide may decrease the excretion rate of Calcium Carbonate which could result in a higher serum level.Approved
Methylene blueCalcium Carbonate can cause a decrease in the absorption of Methylene blue resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
MethylphenidateCalcium Carbonate can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
MethylprednisoloneThe bioavailability of Methylprednisolone can be decreased when combined with Calcium Carbonate.Approved, Vet Approved
MetildigoxinCalcium Carbonate may increase the arrhythmogenic activities of Metildigoxin.Experimental
MetolazoneMetolazone may decrease the excretion rate of Calcium Carbonate which could result in a higher serum level.Approved
MevastatinThe serum concentration of Mevastatin can be decreased when it is combined with Calcium Carbonate.Experimental
MibefradilThe therapeutic efficacy of Mibefradil can be decreased when used in combination with Calcium Carbonate.Withdrawn
MidomafetamineCalcium Carbonate may decrease the excretion rate of 3,4-Methylenedioxymethamphetamine which could result in a higher serum level.Experimental, Illicit
MinocyclineCalcium Carbonate can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MisoprostolThe risk or severity of adverse effects can be increased when Calcium Carbonate is combined with Misoprostol.Approved
MMDACalcium Carbonate may decrease the excretion rate of MMDA which could result in a higher serum level.Experimental, Illicit
MoricizineCalcium Carbonate can cause a decrease in the absorption of Moricizine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
Mycophenolic acidCalcium Carbonate can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
NaftopidilThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Calcium Carbonate.Investigational
Nalidixic AcidCalcium Carbonate can cause a decrease in the absorption of Nalidixic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
NCX 1022The bioavailability of NCX 1022 can be decreased when combined with Calcium Carbonate.Investigational
NemonoxacinCalcium Carbonate can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
NicardipineThe therapeutic efficacy of Nicardipine can be decreased when used in combination with Calcium Carbonate.Approved
NifedipineThe therapeutic efficacy of Nifedipine can be decreased when used in combination with Calcium Carbonate.Approved
NiguldipineThe therapeutic efficacy of Niguldipine can be decreased when used in combination with Calcium Carbonate.Experimental
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Calcium Carbonate.Approved, Investigational
NiludipineThe therapeutic efficacy of Niludipine can be decreased when used in combination with Calcium Carbonate.Experimental
NilvadipineThe therapeutic efficacy of Nilvadipine can be decreased when used in combination with Calcium Carbonate.Approved
NimesulideThe therapeutic efficacy of Nimesulide can be decreased when used in combination with Calcium Carbonate.Approved, Withdrawn
NimodipineThe therapeutic efficacy of Nimodipine can be decreased when used in combination with Calcium Carbonate.Approved
NisoldipineThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Calcium Carbonate.Approved
NitrendipineThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium Carbonate.Approved
NorfloxacinCalcium Carbonate can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
OleandrinCalcium Carbonate may increase the arrhythmogenic activities of Oleandrin.Experimental
Oleoyl-estroneThe bioavailability of Oleoyl-estrone can be decreased when combined with Calcium Carbonate.Investigational
OtiloniumThe therapeutic efficacy of Otilonium can be decreased when used in combination with Calcium Carbonate.Experimental
OuabainCalcium Carbonate may increase the arrhythmogenic activities of Ouabain.Approved
Oxolinic acidCalcium Carbonate can cause a decrease in the absorption of Oxolinic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
PamidronateThe serum concentration of Pamidronate can be decreased when it is combined with Calcium Carbonate.Approved
ParamethasoneThe bioavailability of Paramethasone can be decreased when combined with Calcium Carbonate.Approved
ParicalcitolThe risk or severity of adverse effects can be increased when Calcium Carbonate is combined with Paricalcitol.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be decreased when it is combined with Calcium Carbonate.Approved
PazufloxacinCalcium Carbonate can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
PefloxacinCalcium Carbonate can cause a decrease in the absorption of Pefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PenicillamineThe serum concentration of Penicillamine can be decreased when it is combined with Calcium Carbonate.Approved
PerazineCalcium Carbonate can cause a decrease in the absorption of Perazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
PerhexilineThe therapeutic efficacy of Perhexiline can be decreased when used in combination with Calcium Carbonate.Approved
PerphenazineCalcium Carbonate can cause a decrease in the absorption of Perphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PeruvosideCalcium Carbonate may increase the arrhythmogenic activities of Peruvoside.Experimental
PhentermineCalcium Carbonate may decrease the excretion rate of Phentermine which could result in a higher serum level.Approved, Illicit
PinaveriumThe therapeutic efficacy of Pinaverium can be decreased when used in combination with Calcium Carbonate.Approved
Pipemidic acidCalcium Carbonate can cause a decrease in the absorption of Pipemidic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Piromidic acidCalcium Carbonate can cause a decrease in the absorption of Piromidic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Calcium Carbonate.Approved
PolythiazidePolythiazide may decrease the excretion rate of Calcium Carbonate which could result in a higher serum level.Approved
PrasteroneThe bioavailability of Prasterone can be decreased when combined with Calcium Carbonate.Approved, Nutraceutical
Prasterone sulfateThe bioavailability of Prasterone sulfate can be decreased when combined with Calcium Carbonate.Investigational
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Calcium Carbonate.Approved
PrednicarbateThe bioavailability of Prednicarbate can be decreased when combined with Calcium Carbonate.Approved
PrednisoloneThe bioavailability of Prednisolone can be decreased when combined with Calcium Carbonate.Approved, Vet Approved
PrednisoneThe bioavailability of Prednisone can be decreased when combined with Calcium Carbonate.Approved, Vet Approved
PregabalinThe therapeutic efficacy of Pregabalin can be decreased when used in combination with Calcium Carbonate.Approved, Illicit, Investigational
PregnenoloneThe bioavailability of Pregnenolone can be decreased when combined with Calcium Carbonate.Experimental
PrenylamineThe therapeutic efficacy of Prenylamine can be decreased when used in combination with Calcium Carbonate.Withdrawn
ProchlorperazineCalcium Carbonate can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
PromazineCalcium Carbonate can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
PromethazineCalcium Carbonate can cause a decrease in the absorption of Promethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PropiopromazineCalcium Carbonate can cause a decrease in the absorption of Propiopromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Vet Approved
ProscillaridinCalcium Carbonate may increase the arrhythmogenic activities of Proscillaridin.Experimental
PrulifloxacinCalcium Carbonate can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
PseudoephedrineCalcium Carbonate may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level.Approved
QuinethazoneQuinethazone may decrease the excretion rate of Calcium Carbonate which could result in a higher serum level.Approved
QuinidineCalcium Carbonate may decrease the excretion rate of Quinidine which could result in a higher serum level.Approved
QuinineThe serum concentration of Quinine can be increased when it is combined with Calcium Carbonate.Approved
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Calcium Carbonate.Approved
RimexoloneThe bioavailability of Rimexolone can be decreased when combined with Calcium Carbonate.Approved
RiociguatThe serum concentration of Riociguat can be decreased when it is combined with Calcium Carbonate.Approved
RisedronateThe serum concentration of Risedronate can be decreased when it is combined with Calcium Carbonate.Approved, Investigational
RitobegronCalcium Carbonate may decrease the excretion rate of Ritobegron which could result in a higher serum level.Investigational
RosoxacinCalcium Carbonate can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
RosuvastatinThe serum concentration of Rosuvastatin can be decreased when it is combined with Calcium Carbonate.Approved
RufloxacinCalcium Carbonate can cause a decrease in the absorption of Rufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
SimvastatinThe serum concentration of Simvastatin can be decreased when it is combined with Calcium Carbonate.Approved
SitafloxacinCalcium Carbonate can cause a decrease in the absorption of Sitafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Sodium glycerophosphateCalcium Carbonate can cause a decrease in the absorption of Sodium glycerophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Sodium phosphateCalcium Carbonate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SotalolThe serum concentration of Sotalol can be decreased when it is combined with Calcium Carbonate.Approved
SparfloxacinCalcium Carbonate can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Strontium ranelateThe serum concentration of Strontium ranelate can be decreased when it is combined with Calcium Carbonate.Approved
SulpirideThe serum concentration of Sulpiride can be decreased when it is combined with Calcium Carbonate.Approved
Technetium Tc-99m etidronateThe serum concentration of Technetium Tc-99m etidronate can be decreased when it is combined with Calcium Carbonate.Approved
Technetium Tc-99m medronateThe serum concentration of Technetium Tc-99m medronate can be decreased when it is combined with Calcium Carbonate.Approved
TemafloxacinCalcium Carbonate can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
TerodilineThe therapeutic efficacy of Terodiline can be decreased when used in combination with Calcium Carbonate.Experimental
TetrahydropalmatineThe therapeutic efficacy of Tetrahydropalmatine can be decreased when used in combination with Calcium Carbonate.Investigational
ThiazinamCalcium Carbonate can cause a decrease in the absorption of Thiazinam resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
ThiethylperazineCalcium Carbonate can cause a decrease in the absorption of Thiethylperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
ThioridazineCalcium Carbonate can cause a decrease in the absorption of Thioridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
Thyroid, porcineThe therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Calcium Carbonate.Approved
Tiludronic acidThe serum concentration of Tiludronic acid can be decreased when it is combined with Calcium Carbonate.Approved, Vet Approved
TixocortolThe bioavailability of Tixocortol can be decreased when combined with Calcium Carbonate.Approved
TolevamerThe risk or severity of adverse effects can be increased when Calcium Carbonate is combined with Tolevamer.Approved
Tolfenamic AcidThe therapeutic efficacy of Tolfenamic Acid can be decreased when used in combination with Calcium Carbonate.Approved
TranilastThe therapeutic efficacy of Tranilast can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
TriamcinoloneThe bioavailability of Triamcinolone can be decreased when combined with Calcium Carbonate.Approved, Vet Approved
TrichlormethiazideTrichlormethiazide may decrease the excretion rate of Calcium Carbonate which could result in a higher serum level.Approved, Vet Approved
TriethylenetetramineCalcium Carbonate can cause a decrease in the absorption of Triethylenetetramine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
TrifluoperazineCalcium Carbonate can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
TriflupromazineCalcium Carbonate can cause a decrease in the absorption of Triflupromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
TrovafloxacinCalcium Carbonate can cause a decrease in the absorption of Trovafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
UbidecarenoneThe serum concentration of Ubidecarenone can be decreased when it is combined with Calcium Carbonate.Experimental
VerapamilThe therapeutic efficacy of Verapamil can be decreased when used in combination with Calcium Carbonate.Approved
VinpocetineThe therapeutic efficacy of Vinpocetine can be decreased when used in combination with Calcium Carbonate.Investigational
XylometazolineThe therapeutic efficacy of Xylometazoline can be decreased when used in combination with Calcium Carbonate.Approved
ZiconotideThe therapeutic efficacy of Ziconotide can be decreased when used in combination with Calcium Carbonate.Approved
Zoledronic acidThe serum concentration of Zoledronic acid can be decreased when it is combined with Calcium Carbonate.Approved
Food Interactions
  • Food increases the absorption of calcium carbonate.

References

Synthesis Reference

Nobuo Someya, Tadao Kitazato, Takao Fujikawa, Yasuo Manabe, "Sintered body of calcium carbonate and process for producing same." U.S. Patent US5187125, issued May, 1940.

US5187125
General References
Not Available
External Links
KEGG Drug
D00932
KEGG Compound
C08129
PubChem Compound
10112
PubChem Substance
310264878
ChemSpider
9708
ChEBI
3311
ChEMBL
CHEMBL1200539
PharmGKB
PA448726
Wikipedia
Calcium_carbonate
ATC Codes
A11GB01 — Ascorbic acid (vit c) and calciumA12AA04 — Calcium carbonateA02AC01 — Calcium carbonate
AHFS Codes
  • 56:04.00 — Antacids and Adsorbents
  • 88:29.00* — Minerals
  • 40:12.00 — Replacement Preparations

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1CompletedBasic ScienceHealthy Volunteers2
1CompletedBasic ScienceHuman Immunodeficiency Virus (HIV) Infections1
1CompletedTreatmentAdvanced Solid Tumors1
1CompletedTreatmentDiabetic Nephropathies1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections3
1RecruitingPreventionMalignant Neoplasm of Colon1
2CompletedPreventionAflatoxicosis1
2CompletedPreventionDietary Carcinogenesis1
2CompletedTreatmentArthritis, Juvenile Rheumatoid1
2CompletedTreatmentDiabetic Nephropathies1
2CompletedTreatmentEnd-Stage Renal Disease (ESRD)1
2CompletedTreatmentGaucher's Disease / Osteopenia1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
2CompletedTreatmentHyperparathyroidism, Secondary / Renal Osteodystrophy1
2CompletedTreatmentInfection, Human Immunodeficiency Virus I1
2CompletedTreatmentBone destruction / Osteopenia1
2CompletedTreatmentBone destruction / Postmenopausal Osteoporosis (PMO)1
2RecruitingTreatmentHyperphosphataemia / Hyperphosphataemia in Chronic Kidney Disease1
2Unknown StatusBasic ScienceMetastatic Colorectal Cancers1
2, 3CompletedPreventionAdenoma benign / Colorectal Cancers / Polyps1
3Active Not RecruitingTreatmentHemodialysis-dependent patients / Hyperphosphataemia1
3CompletedHealth Services ResearchDeficiency, Vitamin D1
3CompletedTreatmentHyperphosphataemia1
3CompletedTreatmentMalignant Lymphomas / Non-Hodgkin's Lymphoma (NHL)1
3Not Yet RecruitingTreatmentLiver Cirrhosis3
3RecruitingTreatmentAging / Pre-Diabetic1
3RecruitingTreatmentOsteopenia1
3TerminatedPreventionDiarrhea1
4Active Not RecruitingTreatmentTooth Bleaching / Tooth Sensitivity1
4CompletedTreatmentBMI >27 kg/m2 / BMI >30 kg/m21
4CompletedTreatmentCardiovascular Events / Hemodialysis-dependent patients / Hyperphosphataemia1
4CompletedTreatmentEmergency / Indigestion / Pain1
4CompletedTreatmentNutritional Rickets1
4CompletedTreatmentStage 3 Chronic Kidney Disease1
4Enrolling by InvitationTreatmentBone Diseases, Metabolic / Hyperphosphataemia / Renal Insufficiency,Chronic1
4RecruitingTreatmentHyperphosphataemia1
4Unknown StatusTreatmentOther Nonspecific Abnormal Serum Enzyme Levels1
Not AvailableActive Not RecruitingSupportive CarePrimary Hyperparathyroidism1
Not AvailableCompletedTreatmentCardiovascular Mortality1
Not AvailableCompletedTreatmentBone destruction / Cystic Fibrosis (CF)1
Not AvailableCompletedTreatmentEnd Stage Renal Disease (ESRD) / Hemodialysis-dependent patients / Intimal Media Thickness1
Not AvailableNot Yet RecruitingTreatmentType 2 Diabetes Mellitus1
Not AvailableRecruitingTreatmentBone destruction / Differentiated Thyroid Cancer (DTC)1
Not AvailableWithdrawnTreatmentEnd-Stage Renal Disease (ESRD) / Hyperphosphataemia / Insulin Resistance / Kidney Failure,Chronic1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
TabletOral1000 mg/1
TabletOral750 mg/1
Tablet, chewableOral750 1/1
PasteDental36.4 g/130g
TabletOral
Powder, for solutionOral
PowderOral1 g/g
SuspensionOral1250 mg/5mL
TabletOral1250 mg/1
TabletOral648 mg/1
TabletOral1.5 g
WaferOral
TabletOral625 mg
TabletOral1.25 g
Tablet, chewableOral1177 mg/1
Gum, chewingOral500 mg/1
GranuleOral750 mg/g
PowderOral
TabletOral1000 mg
LiquidOral1250 mg/40mL
SolutionOral1250 mg/34mL
Capsule, gelatin coatedOral
SuspensionOral
Kit
Tablet, chewableOral1000 mg/1
Tablet, chewableOral500 mg/1
Tablet, chewableOral750 mg/1
Tablet, chewableOral
Tablet, chewableOral420 mg/1
PowderOral1000 mg/1
Tablet, chewableOral350 mg/492mg
Paste, dentifriceDental31.25 g/100g
Tablet, film coatedOral
Bar, chewableOral1177 mg/1
Tablet, chewableOral420 1/1
TabletOral420 mg/1
PasteDental
PasteDental51 g/150g
TabletOral250 mg
Tablet, coatedOral
LiquidTopical
LiquidOral
Tablet, chewableOral648 mg/1
PowderTopical
Paste, dentifriceDental15.85 g/100g
Paste, dentifriceDental
Tablet, chewableOral400 mg/1
TabletOral420 mg
TabletOral500 mg/1
TabletOral500 mg
TabletOral750 mg
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6814978Yes2002-02-262022-02-26Us
US6165513Yes1998-12-102018-12-10Us
US5994329Yes1999-01-172019-01-17Us
US6015801Yes1999-01-172019-01-17Us
US6432932Yes1999-01-172019-01-17Us
US6465443Yes1999-02-142019-02-14Us
US5989588Yes1998-03-302018-03-30Us

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility128.0 mg/mLALOGPS
logP0.47ALOGPS
logP0.25ChemAxon
logS-0.08ALOGPS
pKa (Strongest Acidic)6.05ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area63.19 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity31.17 m3·mol-1ChemAxon
Polarizability3.52 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as organic carbonic acids. These are compounds comprising the carbonic acid functional group.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Organic carbonic acids and derivatives
Sub Class
Organic carbonic acids
Direct Parent
Organic carbonic acids
Alternative Parents
Carbonate salts / Organic calcium salts / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Carbonate salt / Carbonic acid / Organic calcium salt / Organic oxygen compound / Organic oxide / Hydrocarbon derivative / Organic salt / Organooxygen compound / Carbonyl group / Aliphatic acyclic compound
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
calcium salt, one-carbon compound, carbonate salt (CHEBI:3311)

Drug created on August 09, 2010 11:35 / Updated on October 23, 2017 14:13